Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 138,616 shares at $2.44 ($333K) on 2019-09-13, disclosed to the SEC on 2019-09-17.
Open-market purchase of $333k LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.38 | 28,225 | $67K | 20.2% |
| 2 | $2.39 | 21,652 | $52K | 15.5% |
| 3 | $2.40 | 34,087 | $82K | 24.5% |
| 4 | $2.41 | 24,772 | $60K | 17.9% |
| 5 | $2.44 | 29,880 | $73K | 21.9% |
| Total | $2.40 avg | 138,616 |
| $333K |
| 100% |
| Filing → |
| LXRX | BUY | 2026-02-23 | $220K | — | Filing → |
| LXRX | BUY | 2026-02-18 | $353K | — | Filing → |
| LXRX | BUY | 2023-10-12 | $2.2M | — | Filing → |